Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023 08:30 ET
|
Disc Medicine Inc
Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include adolescentsData from all adult patients in BEACON to be presented in...
Disc Medicine to Participate in Upcoming Investor Conferences
November 08, 2023 16:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates
November 02, 2023 09:00 ET
|
Disc Medicine Inc
Completion of enrollment for phase 2 BEACON and AURORA studies of bitopertin in erythropoietic protoporphyria (EPP)Oral presentation at ASH meeting of updated interim data from BEACON, including a...
Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce
October 23, 2023 09:15 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers
October 03, 2023 08:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera
September 20, 2023 16:30 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine to Participate in Upcoming Investor Conferences
August 30, 2023 16:15 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update
August 11, 2023 08:00 ET
|
Disc Medicine Inc
Presented positive initial safety and efficacy data from the BEACON trial at the European Hematology Association (EHA) Congress in June 2023; data from all patients in BEACON to be presented year-end...
Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)
July 27, 2023 09:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 22, 2023 16:15 ET
|
Disc Medicine Inc
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...